<DOC>
	<DOCNO>NCT00792168</DOCNO>
	<brief_summary>Primary : identify physiologic indicator venlafaxine treatment response use quantitative EEG ( QEEG ) cordance , determine cordance change specifically associate response venlafaxine ; Secondary : determine cordance change early course ( i.e. , prior improvement clinical symptom ) venlafaxine ( another antidepressant venlafaxine clinically indicate particular patient ) predictive later clinical response .</brief_summary>
	<brief_title>Physiologic Monitoring Antidepressant Treatment Response</brief_title>
	<detailed_description>After one-week single-blind placebo lead , subject randomly assign either venlafaxine placebo 8 week . They undergo 6 QEEG study ( end wash-in , 48 hour , 1 week , 2 week , 4 week , 8 week randomize treatment ) , examiner self-ratings mood , anxiety , clinical status time record ( Ham-D , MADRS , Ham-A , SCL-90 , Beck , LIFE , CGI ) ass improvement . Any subject significant deterioration mood and/or suicidal ideation 8 week trial drop study place open treatment . At end 8 week , code broken subject maintained/re-assigned open-label treatment venlafaxine additional 10 month wish . However , subject 's primary physician believe another clinically available antidepressant would indicate instead venlafaxine ( due history prior non-response venlafaxine , etc . ) , indicate antidepressant medication administer . The antidepressant medication recommend primary physician provide free charge one-year period . Tricyclic antidepressant monoamine oxidase inhibitor include due great possibility serious clinical sequela old medication . The open-label phase consist regular monitoring laboratory interval three day one week begin new antidepressant medication , monthly clinical visit ( frequently clinically indicate ) QEEG record assessment mood clinical status laboratory psychiatrist ensure subject get appropriate care primary physician . Drug dose adjust use standard clinical practice subject 's primary physician community , subject remain venlafaxine , dosage may increase high 225 mg/day phase . Subjects one additional follow-up QEEG end open-label phase significant clinical improvement detect ( defined resolution DSM-IV symptom , Ham-D &lt; 9 ) . After subject 's depression resolve , continue monitor give medication free charge remainder one-year period , see clinically primary physician community . A study psychiatrist available consultation case clinical necessity primary physician contact . Subjects venlafaxine clinically indicate and/or subject refuse placebo portion study may allow bypass placebo-controlled phase proceed directly open-label phase .</detailed_description>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>All subject meet DSMIV criterion depression basis SCIDP interview , subject placebo control phase study score 17item HamD &gt; 18 ( item # 1 &gt; 2 ) . Subjects meet criterion recruitment , oneweek single blind placebo washin . Study include outpatient . All subject serious medical illness . The investigator exclude patient also meet criterion follow group axis I diagnosis : delirium dementia substancerelated disorder schizophrenia psychotic disorder eat disorder . In addition , patient meet criterion cluster A B axis II diagnose exclude . Subjects history current past active suicidal ideation , suicide attempt exclude placebocontrolled phase study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
</DOC>